Leridistim
Anemia
Memorial Sloan Kettering Cancer Centerprotein_peptidePhase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 42/ 100
- Competitive Position
- 89/ 100
Competitive context
13 Active assets in the Anemia cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Epoetin Alfa Mayo Clinic | Phase 4 | BBB |
Erythropoietin Human Recombinant Second Affiliated Hospital, School of Medicine, Zhejiang University | Phase 4 | BBB |
Epoetin Beta Institut du Cancer de Montpellier - Val d'Aurelle | Phase 4 | BBB |
Ferric Carboxymaltose [Ferinject] Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) | Phase 4 | BBB |
Darbepoetin Alfa Amgen | Phase 3 | BBB |
View all 50 →
Same molecule, other indications
Leridistim is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →